dronabinol has been researched along with gw9662 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atez, F; Parker, J; Patel, R; Rossetti, RG; Skulas, A; Zurier, RB | 1 |
| Fishbein-Kaminietsky, M; Gafni, M; Sarne, Y | 1 |
2 other study(ies) available for dronabinol and gw9662
| Article | Year |
|---|---|
Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid.
Topics: Anilides; Dronabinol; Humans; Interleukin-6; Macrophages; PPAR gamma | 2008 |
Ultralow doses of cannabinoid drugs protect the mouse brain from inflammation-induced cognitive damage.
Topics: Anilides; Animals; Arachidonic Acids; Brain; Camphanes; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cognition Disorders; Cyclooxygenase 2; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Encephalitis; Lipopolysaccharides; Male; Mice; Mice, Inbred ICR; PPAR gamma; Pyrazoles; Recognition, Psychology | 2014 |